All Atrial fibrillation articles
Xarelto▼ (rivaroxaban) patient counselling checklist for HCPs—initiating, or transitioning to rivaroxaban for stroke prevention in patients with NVAF*
This checklist was developed from content provided by Bayer plc and the format was developed by Guidelines. Information intended for healthcare professionals only.
View prescribing information and adverse event reporting information
*Rivaroxaban is indicated for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.
PP-XAR-GB-1993 March 2021
This video has been commissioned and funded by Bayer plc and developed in partnership with Guidelines.
View Xarelto▼(rivaroxaban) prescribing information and adverse event reporting
PP-XAR-GB-1924 January 2021
Independent professional body guideline
Recommendations for primary care on the role of oral anticoagulant treatment in people with non-valvular atrial fibrillation.
Working party guideline/algorithm
This guideline was developed by a multidisciplinary expert panel: Fay M et al with the support of an educational grant from Bayer plc.
Read the latest recommendations on the management of atrial fibrillation and ventricular arrhythmias in acute coronary syndrome, coronary heart disease, and left-ventricular dysfunction as well as arrhythmias associated with cardiac arrest and coronary artery bypass graft.